"Cytisinicline: A Promising Treatment for Smoking Cessation"
A randomized clinical trial involving 810 adults who smoked found that both a 6-week and a 12-week course of cytisinicline, a plant-based alkaloid, were more effective than placebo in promoting smoking cessation. The novel dosing regimen of cytisinicline, which binds to nicotine receptors, demonstrated higher continuous smoking abstinence rates during treatment and up to 24 weeks after treatment. The drug was well tolerated, with nausea, abnormal dreams, and insomnia being the most common side effects. This study suggests that cytisinicline, along with behavioral support, could be a new treatment option for nicotine dependence.
